December 14, 2014

FDA: Cyramza approval now includes non-small-cell lung CA

FDA: cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.

Cyramza was first approved in April to treat advanced or (GEJ) adenocarcinoma, and approval was widened in November to include advanced gastric or GEJ adenocarcinoma in combination with paclitaxel.

Clinical side effects have included neutropenia, stomatitis, fatigue, severe bleeding, blood clots, raised blood pressure, and impaired wound healing.

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More information: More Information

Health News Copyright © 2014 HealthDay. All rights reserved.

Citation: FDA: Cyramza approval now includes non-small-cell lung CA (2014, December 14) retrieved 24 April 2024 from https://medicalxpress.com/news/2014-12-fda-cyramza-non-small-cell-lung-ca.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Cyramza approved for stomach cancer
 shares

Feedback to editors
The consumption of certain food additive emulsifiers could be associated with the risk of developing type 2 diabetes

12 hours ago
Perinatal transmission of HIV can lead to cognitive deficits

12 hours ago
Study finds suicidal behaviors increased by over 50% in Catalonia, Spain after the COVID-19 pandemic

14 hours ago
Why do we move slower the older we get? New study delivers answers

14 hours ago
Stress activates brain regions linked to alcohol use disorder differently for women than men, finds study

15 hours ago
Chemical tool illuminates pathways used by dopamine, opioids and other neuronal signals

15 hours ago
Gentle defibrillation for the heart: A milder method developed by researchers for cardiac arrhythmias

16 hours ago
Q&A: Research shows neural connection between learning a second language and learning to code

16 hours ago
Gut microbiota acts like an auxiliary liver, study finds

16 hours ago
Higher light levels may improve cognitive performance

16 hours ago
Load comments (0)